Reilly Financial Advisors’s Haemonetics HAE Stock Holding History

Reilly Financial Advisors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-125	Closed	-$14K	–	1031
2021 Q1	$14K	Hold	125	–	–	﹤0.01%	621
2020 Q4	$15K	Hold	125	–	–	﹤0.01%	545
2020 Q3	$11K	Hold	125	–	–	﹤0.01%	553
2020 Q2	$11K	Hold	125	–	–	﹤0.01%	556
2020 Q1	$12K	Hold	125	–	–	﹤0.01%	523
2019 Q4	$14K	Hold	125	–	–	﹤0.01%	568
2019 Q3	$16K	Hold	125	–	–	﹤0.01%	549
2019 Q2	$15K	Hold	125	–	–	﹤0.01%	586
2019 Q1	$11K	Hold	125	–	–	﹤0.01%	662
2018 Q4	$13K	Hold	125	–	–	﹤0.01%	586
2018 Q3	$14K	Hold	125	–	–	﹤0.01%	627
2018 Q2	$11K	Hold	125	–	–	﹤0.01%	642
2018 Q1	$9K	Sell	125 -45	-26%	-$3.09K	﹤0.01%	668
2017 Q4	$10K	Hold	170	–	–	﹤0.01%	652
2017 Q3	$8K	Hold	170	–	–	﹤0.01%	671
2017 Q2	$7K	Hold	170	–	–	﹤0.01%	715
2017 Q1	$7K	Buy	+170	New	+$6.64K	﹤0.01%	674

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

LCOV

London Company of Virginia Richmond, Virginia $17.5B AUM 29.92% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.97B AUM 15.72% 1-Year Est. Return

Reilly Financial Advisors's HAE Position: Q2 2021 in Review

Reilly Financial Advisors sold out of Haemonetics (HAE) in Q2 2021, closing a stake of 125 shares — an estimated $14K sold.

Reilly Financial Advisors first reported a position in HAE in Q1 2017 and held it in 17 quarters. The position peaked at $16K in Q3 2019. 258 funds tracked by Wall St. Rank hold HAE as of Q2 2021.

Reilly Financial Advisors reported no remaining Haemonetics position as of Q2 2021 after selling out during the quarter.
Reilly Financial Advisors sold 125 Haemonetics shares in Q2 2021, an estimated $14K.
Reilly Financial Advisors first reported a position in Haemonetics in Q1 2017 and held it in 17 quarters.
Reilly Financial Advisors's Haemonetics position peaked at $16K in Q3 2019.
258 funds tracked by Wall St. Rank held Haemonetics as of Q2 2021.

Based on Reilly Financial Advisors's 13F filing for Q2 2021, filed 3 Aug 2021.